Q4 2025 Acurx Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Acurx Pharmaceuticals Inc (ACXP) received approximately $1.4 million from the execution of Series F Warrants, boosting their financial resources.
- The company presented promising microbiome-sparing data at IDWeek, highlighting the potential of their DNA pol IIIC inhibitor pipeline.
- A new patent for Pol IIIC inhibitors was granted, extending protection until December 2039, which strengthens their intellectual property portfolio.
- Ibezapolstat showed a 96% clinical cure rate in Phase II trials for C. difficile infection, with no recurrence in patients, indicating strong efficacy.
- The company ended 2025 with $7.6 million in cash, a significant increase from $3.7 million at the end of 2024, reflecting improved financial stability.
- Acurx Pharmaceuticals Inc (ACXP) reported a net loss of $1.6 million for Q4 2025, although this was an improvement from the previous year.
- Research and development expenses decreased significantly, which could indicate a slowdown in new project initiation or progression.
- The company is still in the early stages of their ibezapolstat clinical trial program for recurrent CDI, with full enrollment expected to take 12 to 15 months.
- There is uncertainty regarding the FDA's new one-trial requirement, which could impact the timeline and strategy for clinical trials.
- The company relies on external funding opportunities and alternative financial pathways to support their Phase III clinical trial program, indicating potential financial constraints.
Greetings and welcome to Acurx Pharmaceuticals conference call to discuss full year and fourth quarter 2025 financial results. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Rob Shawah, Chief Financial Officer. Thank you. Please go ahead.
Thank you, [Donna]. Good morning, and welcome to our call. This morning, we issued a press release providing financial results and company highlights for the year ended and fourth quarter 2025, which is available on our website at acurxpharma.com.
Joining me today are Bob DeLuccia, Executive Chairman of Acurx; Dr. Michael Silverman, Medical Director of Acurx who will be available for questions related to our R&D activities and strategy during the Q&A period; and David Luci, President and CEO of Acurx who will start by providing a corporate update and outlook.
Following that, I'll provide some highlights of the financials from the year and fourth
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
